You are about to leave the Nuvalent website.

Nuvalent does not endorse or take responsibility for any information or statements made on external sites.

Do you wish to continue?

Cancel Continue
Nuvalent

News Releases

Nuvalent to Participate in the Wells Fargo 2022 Healthcare Conference

CAMBRIDGE, Mass., Sept. 1, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, will participate in a fireside chat at the Wells Fargo 2022 Healthcare Conference on Thursday, September 8, 2022, at 2:35 p.m. ET in Boston.

A live webcast will be available in the Investors section of the company's website at www.nuvalent.com, and archived for 30 days following the presentation.

About Nuvalent

Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive non-small cell lung cancer (NSCLC), along with multiple discovery-stage research programs. We routinely post information that may be important to investors on our website at www.nuvalent.com. Follow us on Twitter (@nuvalent) and LinkedIn.

 

SOURCE Nuvalent, Inc.

Investor Contact:
Chelcie Lister
THRUST Strategic Communications
chelcie@thrustsc.com

Media Contact:
Amanda Sellers
Verge Scientific Communications
asellers@vergescientific.com

The information in Nuvalent’s press releases is accurate only as of the date of issuance. Nuvalent assumes no duty to update or revise the information contained in the press releases after their original release date.